Transplant-Eligible, CAR T Considered: How Do We Decide?
Panelists discuss how, when selecting among chimeric antigen receptor T-cell (CAR T) therapies, medical professionals typically consider several key factors: the specific cancer type and its CD19/BCMA expression, FDA-approved indications for each therapy, the patient’s prior treatments and response history, the therapy’s documented efficacy and safety profile, manufacturing time and availability, and center-specific experience with different products. Patient-specific factors like comorbidities and disease burden also influence the decision.
Video content above is prompted by the following:
- If you proceed with CAR T, how would you approach selection among the available CAR T therapies?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
